Table 2.

	GC-ON (N = 10)	rGC-ON (N = 10)	p-values
			GC-ON vs. rGC-ON
Age at lumbar puncture (years)	32 [11] (18–49)	30 [7] (25–71)	0.6
Female sex, N (%)	10 (100)	4 (40)	0.03
Median EDSS (range)	2 (1.5–4)	3 (2–4)	0.08
Cerebral T2-lesion count	4.5 [3.4] (1–11)	8.0 [5.1] (3–19)	0.09
Timespan between acute symptom and steroid application (days)	10 [7] (3–24)	5 [4] (0–14)	0.09
Median baseline VA (range)	0.2 (0.1–0.8)	0.05 (0–0.3)	0.004
Median VA after treatment (range)	0.69 (0.5–1.0)	0.05 (0–0.4)	< 0.001
Pathological VEP, N (%)	10 (100)	10 (100)	1.0
P 100 latency (ms), N	123 [9] (113–138), 8/10	142 [17] (113–163), 6/10	0.02
CSF Cell count/μl	8 [8] (0–23)	10 [10] (1–35)	0.6
CSF protein (mg/dl)	325 [55] (234–402)	420 [180] (250–825)	0.1
Qalb	3.9 [0.9] (2.6–5.4)	5.7 [3] (3.2–11.5)	0.09
Rel. monocyte fraction	0.13 [0.25] (0.03–0.25)	0.22 [0.26] (0.05–0.80)	0.3
CSF-MIF	8.4 [2.5] (4.0–12.2)	8.9 [2.7] (5.3–13.4)	0.7

N = number of participants; unless otherwise reported mean [standard deviation] (range) is given. CON = disease controls, CSF = cerebrospinal fluid, MIF = Macrophage migration inhibitory factor, EDSS = Expanded disability status scale, GC-ON = glucocorticoid responsive optic neuritis, Qalb = albumin quotient, Rel. = relative, rGC-ON = non-glucocorticoid-responsive optic neuritis, VA = visual acuity. Disease duration was defined as the timespan between symptom onset and the date of lumbar puncture. Mean P100 latency only could be estimated from patients with stimulation response. For continuous variables, an independent-samples t test or a Mann-Whitney-U test was conducted, while for binary variables, a chi-squared test was calculated. P-values ≤ 0.05 were deemed to be statistically significant.